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Background: The addition of a DDP4-inhibitor to existing insulin therapy reduces HbA1c. However, no data exist
about the addition of these agents at the beginning of insulin treatment in type 2 diabetes while this could
especially be interesting because it is during this period that considerable residual beta cell function is still present.
The benefit of such a strategy could be a lower insulin dose required for glycemic control. The hypothesis of our
study was that adding a DPP4-inhibitor at the beginning of insulin treatment could lead to less exogenous insulin
requirement, a reduction of hyperinsulinemia and side effects (hypoglycemia and weight gain), less glucose
variability and improvement of insulin and glucagon dynamics during a mixed meal test.
Results: In this small clinical trial (trial registration NTR2022) 9 patients were randomized to receive vildagliptin and
6 to receive placebo in addition to start of once daily insulin treatment. Unfortunately, due to a difficult inclusion,
the preset sample size of 40 patients could not be met. Median units of insulin at the end of the study was 47 U in
the placebo group and 34 U in the vildagliptin group. Median glycemic variability (SD) at the end of study was 2.1
in the placebo group and 1.5 in the vildagliptin group. Median weight gain at the end of study was 3 kg in the
placebo and 0.5 kg in the vildagliptin group. Occurrence of hypoglycemia was low in both groups. Insulin,
C-peptide, glucose and glucagon levels were comparable during mixed meal tests.
Conclusions: This small randomized study did not have sufficient power to detect effects of the addition of
vildagliptin to the start of once daily long-acting insulin. However in our opinion adding a DPP4-inhibitor, especially
in this group remains a very interesting approach. This study could be used as a guidance for larger studies that are
required to investigate the effects of this intervention on insulin requirements, glycemic variability, hypoglycemia
and weight gain.
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Table 1 Base-line characteristics
Placebo Vildagliptin
N 6 9
Age (years) 60 (39–67) 64 (42–67)
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Due to the progressive nature of the disease, most pa-
tients with type 2 diabetes mellitus (DM) ultimately fail
on oral glucose-lowering drugs and therefore require in-
sulin therapy [1,2]. Often considerable doses of insulin
are needed and weight gain and hypoglycemia can occur
[1]. The dipeptidyl peptidase-4 inhibitor (DPP4-inhibi-
tor) vildagliptin is an oral glucose-lowering drug that
leads to glucose-dependent insulin secretion and im-
provement of alpha cell function [3]. A reduction in gly-
cated haemoglobin (HbA1c) and less hypoglycemia was
shown in a previous study adding vildagliptin on top off
an existing insulin regimen [4]. Multiple randomized-
controlled trials investigating the effect of DPP4-
inhibitor added to existing insulin have been performed
since [4-14]; however, no data exist about vildagliptin
use at the start of insulin treatment in patients with
Type 2 DM. Adding a DPP4-inhibitor at the beginning
of insulin treatment could especially be interesting be-
cause it is during this period that considerable residual
beta cell function is still present. The benefit of such a
strategy could be a lower insulin dose necessary for gly-
cemic control. To study this, we titrated insulin in all
patients to the best achievable degree of glycemic con-
trol. Therefore, we did not use HbA1c as the primary
end-point, as most previous studies on DPP4-inhibitors
and insulin did, but the required insulin dose instead.
The aim of the study was to investigate whether or not
the addition of a DPP4-inhibitor to start of insulin treat-
ment could lead to lower exogenous insulin require-
ments together with lower glucose variability, less
weight gain, less hypoglycemia, and improved insulin
and glucagon dynamics after a mixed meal test through
improvement in alpha and beta cell function.BMI (kg/m2) 32 (26–35) 32 (27–34)
Female (%) 17% 22%
Duration DM (years) 5.5 (1–23) 6.0 (2–15)
Prior medication
metformin/SU/TZD/other (%) 100/67/0/33% 100/89/11/22%
Diabetic complications
any microvascular complication (%) 17% 33%
any macrovascular complication (%) 0% 33%
BP (syst/diast in mmHg) 128/78 126/73
HbA1c at start of the trial (mmol/mol) 64 (53–74) 62 (57–73)
(%) 8.0 (7.0-8.9) 7.8 (7.4-8.8)
SD of glucose values (variability) at start
of trial
1.8 (1.0 -2.7) 1.7 (1.2 – 2.6)
All values are in median (range) or percentages.
Any micro- or macrovascular complication was defined as the percentage of
patients who had one or more complications as judged clinically by the
investigator at the moment of inclusion.
Abbreviations: BMI = body mass index, DM= diabetes mellitus, SU = sulfonylurea,
TZD = thiazolidinediones, BP = blood pressure, HbA1c = glycated haemoglobin,
SD = standard deviation.Results
In this study 19 patients were screened and 4 excluded
(reasons for exclusion in (Additional file 1). Nine pa-
tients were randomized to receive vildagliptin and 6 pa-
tients to placebo (Additional file 1). This study was
designed to include 40 patients in 1 year. Since inclusion
rate was much slower than expected, the inclusion
period was extended by more than a year. However, the
number of 40 patients could still not be met and inclu-
sion was therefore terminated after 15 patients.
Table 1 shows the baseline characteristics, which were
comparable in both treatment groups.
Results are summarized in Table 2. Median number of
units of insulin in the placebo group was 47 and in the
vildagliptin group 34. In both groups compliance was
high and HbA1c decrease was comparable. Median gly-
cemic variability (SD) in the placebo group was 1.8 at
the beginning of the study and 2.1 at the end, in thevildagliptin group glycemic variability was 1.7 and 1.5 re-
spectively. Median weight increase at the end of the
study was 3 kg in the placebo and 0.5 kg in the vildaglip-
tin group. Occurrence of hypoglycemia was low and
comparable in both groups. Median systolic blood
pressure change in the vildagliptin group was + 2.5
and −3 mmHg in the placebo group. LDL and SAF
only showed very minor changes.
Comparable levels of glucose, insulin, C-peptide and glu-
cagon were observed in both groups after mixed meal tests
(Additional file 2: Figure S2A-D). Median values of area
under curve (AUC) of glucose and glucagon were 1704
(1439–2279) and 5100 (3030–7620) in the vildagliptin
group and 1773 (1439–1931) and 5310 (3525–10785) in
the placebo group. Median levels of AUC of insulin and C-
peptide were 5295 (1695–24705) and 343050 (106395–
963000) in the vildagliptin group and 3795 (1710–7095)
and 199703 (134550–281250) in the placebo group. Ad-
verse events were reported more often in the placebo
group. These consisted of flu like symptoms (3 patients, all
in the placebo group), tiredness (1 vildagliptin, 1 placebo),
toothache/parodontitis (1 vildagliptin, 1 placebo), a cold (1
vildagliptin), headache and diarrhea (1vildagliptin), revers-
ible increase in gGT (1 placebo, max 165 U/l (normal value:
0–40 U/L)), sensation of tingling in the left arm, which was
reversible during the study (1 placebo), mild orthostatic
symptoms (1 vildagliptin). None of these events were con-




Units insulin 47 (16 – 62) 34 (12 – 62)
Secondary endpoints
Glycemic variability end of study (SD) 2.1 (1.1 – 2.8) 1.5 (1.0 – 3.6)
Change in weight (kg) 3 (−2.5 – 5.5) 0.5 (−2.6 – 4)
Hypoglycemia during the study
(nr per pat)
1.5 (0 – 5) 1.0 (0 – 8)
Change in blood-pressure (mmHg)
Systolic −3 (−12 – 6) 2.5 (−14 – 10)
Diastolic −1.5 (−9 – 3) −0.5 (−6 – 11)
Change in LDL (mmol/L) 0 (−1 – 0.6) −0.3 (−1.4 – 0)
Change in SAF (skin AGEs) (AU) 0.1 (−0.4 – 0.8) 0.15 (−0.4 – 0.6)
Safety
Patients with one or more hypoglycemia
(%)
67% 78%
Patients with severe hypoglycemia (%) 0% 0%
Patients with one or more AE (%) 100% 44%
Patients with one or more SAE (%) 0% 0%
Other
Delta HbA1c (mmol/mol) −6.5 (−18 - 7) −6 (−25 - 4)
(%) −0.6 (−1.6 – 0.6) −0.5 (−2.3 - 0.3)
Compliance (% of tablets taken) 96% 98%
All values are in median (range) or percentages.
Compliance:% of tablets taken during the whole study period.
Delta HbA1c: HbA1c end-begin, −6 means a decrease of 6 points in HbA1c
during the study, a number without – means an increase.
Because of the small sample size no p-values are shown.
Abbreviations; LDL = low-density lipoprotein, SAF = skin autofluorescence,
AGEs = advanced glycation end products, AU = arbitrary units, AE = adverse
event, SAE = serious adverse event, HbA1c = glycated hemoglobin.
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This is the first study investigating the addition of a DPP4-
inhibitor to the start of once-daily long-acting insulin in
insulin-naïve patients. Although this study was set up as a
double-blind parallel-arm placebo-controlled trial, the
sample size is limited and therefore we cannot make con-
clusions about the effect of addition of vildagliptin on
units of insulin at the end of the study, variability, weight,
hypoglycemia or response of insulin, C-peptide or gluca-
gon after a mixed meal test.
This important limitation is due to difficulties in patient
recruitment. In the Netherlands, most patients starting
with once-daily insulin are treated by a general practi-
tioner and not in an (academic) hospital, where this study
was performed. Despite extensive collaboration with many
general practitioners and hospitals in the region, patients
were still difficult to recruit. The small sample size is
therefore too small to have statistical power to confirm or
reject the null hypothesis.However, given the working mechanism of DPP4-
inihibitors and our small sample size, we think it would
be very interesting to investigate our hypothesis in a lar-
ger study. Our small study could potentially serve as a
guidance for such larger studies. From our data it can be
derived that a repeat study would need approximately 46
patients per group. This is based on a median units of
insulin of 40 (SD 17) and 10 units of insulin decrease,
which would be clinically significant (and 25% is com-
parable to the difference in median units of insulin in
our study of 28%). This sample size calculation must be
considered as a rough estimation, given the small sample
size and not-normal distribution of our main end-point,
but at this moment the best estimation available.
Besides the smaller sample size our study differs in two
major design aspects from previous randomized-controlled
trials. First, previous trials investigated the effect of add-on
DPP4-inhibition therapy to existing insulin regimen [4-14],
whereas we investigated the addition of vildagliptin to the
start of insulin therapy in our study. We hypothesized that
adding a DPP4-inhibitor to start of insulin treatment could
lead to less exogenous insulin requirements. This could
lead to a reduction of hyperinsulinemia, which is thought
to have atherogenic and mitogenic effects [15]. Moreover,
lower insulin use could reduce side effects of insulin
treatment such as hypoglycemia and weight gain [1].
The addition of a DPP4-inhibitor to an existing insulin
treatment without the intention to change the insulin
regimen as previous trials did does not reflect clinical
practice in which physicians will choose to alter insulin
schedules. Only in one randomized trial the insulin dose
was changed as a goal in one arm (insulin-increasing
arm) and compared to the addition of sitagliptin to
existing insulin regimen. In that trial, a difference of
25% in insulin dose was described between the insulin-
increasing and the insulin-sitagliptin group [11] to-
gether with a more pronounced HbA1c decrease in the
sitagliptin group. The 25% decrease in units of insulin
found in that study is comparable to the magnitude
(28%) we found.
Second, we used a different end-point compared to
previous trials. In randomized-controlled trials about the
effect of the addition of DPP4-inhibitors to insulin thus
far, HbA1c or glycemic control were used as primary
end-point [4-14]. We chose required units of insulin
since, in our study, we added vildagliptin to the start of
insulin and we aimed at the best glycemic control with
insulin glargine in all patients.
Because a lower insulin dose may lead to less side ef-
fects, we also investigated these as secondary end-points.
The first was hypoglycemia. With improvement of gly-
cemic control, the incidence of hypoglycemic episodes
was expected to increase. This was indeed observed in a
study using sitagliptin [14]. In contrast, a study by
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decrease in HbA1c when vildagliptin was added to an
insulin regimen [4], although this could not be con-
firmed in a study by Kothny et al., using the same
DPP4-inhibitor [10]. Less hypoglycemia, as shown in the
study by Fonseca, could be a result of an improved alpha
cell function, which has been described not only postpran-
dial (reduction in glucagon) but also during the reaction
after induced hypoglycemia when a slightly increased in-
crement of glucagon was seen [3]. In our study occurrence
of hypoglycemia was low in both groups. The second
secondary end-point studied was weight. In contrast
to GLP1-analoga, DPP4-inhibitors do not show a large ef-
fect on weight [16]. Differences in body weight were not
shown in previous randomized-controlled trials with
DPP4 inhibitors in combination with insulin [4-14], except
for one study which compared insulin-increasing therapy
with addition of sitagliptin to existing insulin regimen [9].
The design of that study most resembled ours, and it also
found a difference in required units of insulin between the
groups. Furthermore, that study showed less weight in-
crease in the DPP4 addition group (between-group differ-
ence 1.7 kg in favour of the DPP4-group, which is in
concordance in magnitude with our findings (vildagliptin
group (+0.5 kg), placebo group (+3 kg).
We also studied additional end-points, including glucose
variability. We hypothesize that since variability is deter-
mined by hyperglycemic and hypoglycemic excursions, ef-
fects on alpha cell function could result in less glucose
variability. A decrease in postprandial glucagon could re-
duce hyperglycemic excursions, while an increase in gluca-
gon response following a hypoglycemia could reduce a
hypoglycemic excursion. A decrease in variability has been
reported before from single-arm trials, investigating the ef-
fect of addition of a DPP4-inhibitor to insulin [17,18]. In
our study, median glycemic variability (SD) at the end of
the study was 2.1 in the placebo group and 1.5 in the vilda-
gliptin group. We evaluated responses of insulin, C-
peptide and glucagon during a mixed meal test, which
were comparable in our study. It is difficult to assess insu-
lin and glucagon dynamics in patients taking insulin [14].
All patients were on stable insulin dose, titrated at the fast-
ing glucose levels and all patients were fasting. However,
since exogenous insulin was present at time of testing be-
cause all patients took their glargine at bedtime the day be-
fore the testing, we cannot exclude that measurements are
confounded by exogenous insulin. Since GLP1 could also
have an effect on cardiovascular parameters, these were
also included as an endpoint [19]. Levels for blood pres-
sure, LDL and skin autofluorescence were comparable.
Conclusions
This small randomized study did not have sufficient power
to detect effects of the addition of vildagliptin to thebeginning of once daily long-acting insulin. However in
our opinion adding a DPP4-inhibitor, especially in this
group remains a very interesting approach. This study
could be used as a guidance for larger studies to investi-
gate the effects of this intervention on insulin require-
ments, glycemic variability, hypoglycemia and weight gain.
Methods
Design
This study was set up as a double-blind parallel-arm
placebo-controlled randomized monocenter trial (16 weeks)
comparing the effects of adding vildagliptin or placebo to
the start of insulin in patients with type 2 diabetes mellitus.
Patients were included from December 2009 –May 2012.
Patients
Patients who were scheduled by their treating physician to
start once-daily long-acting insulin were eligible. Inclusion
criteria were: Type 2 DM, failing on maximally tolerated
oral-glucose-lowering medication, BMI 25–35, HbA1c
53–75 mmol/mol (7.0-9.0%) and age 25–75 years. Exclu-
sion criteria were: pregnant women or women in the fer-
tile period of life without adequate birth-control, type I
DM, or another type of DM (for example pancreatic in-
jury, prednisone induced), acute metabolic diabetic com-
plications during the last 6 months, severe cardiac (left
ventricle ejection fraction (LVEF) < 30%) or (a history of)
hepatic failure (transaminases > 3 times elevated), or renal
impairment (creatinine clearance <50 ml/min).
Randomization
Patients were randomized to receive vildagliptin (50 mg
twice daily) or matching placebo (twice daily). To prevent
confounding by BMI, patients were randomized after
stratification for BMI (using two different randomized lists
for BMI 25–30 kg/m2 or BMI 30–35 kg/m2). Consecutive
patients were allocated to the two different groups using
two computer-generated randomized lists (block size 4),
which were stored in sealed envelopes. Randomization and
distribution of blinded study medication was performed by
a person not related to the study (pharmacy). Patients and
care providers were unaware of the randomization code.
Treatment
Besides the study medication, all patients started with
once daily long-acting insulin glargine at bedtime in
combination with a fixed dose of metformin (twice daily
850 mg). Other glucose lowering drugs were terminated.
The combination with metformin was used since this is
standardized approach in Dutch clinical practice. The
dose of insulin glargine was protocolized and titrated
based on daily fasting blood glucose measurements of
the patients and an algorithm comparable to the one
published by Davies et al. [20]. In short, all patients
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formed daily fasting glucose measurements. The insulin
dose was increased based on the mean of the last glu-
cose measurements. This was performed twice a week
for the first 3 weeks and once a week during the remain-
der of the study. The insulin dose was raised as follows:
mean glucose 5.5-6.7 mmol/L: raise of 0–2 units, 6.7-
7.8 mmol/L: 2 units, 7.8-10 mmol/L: 4 units, >10 mmol/
L: 6–8 units increase. The dose was only raised in the
absence of hypoglycemia.
Outcomes
Primary outcome: units of insulin at the end of the
study.
Secondary outcomes: 1) glycemic variability estimated
by the standard deviation (SD) of 48 hours glucose values
at the end of the study as measured by three days blinded
continuous glucose measurement (CGM)) [21] 2) change
in weight 3) hypoglycemia (defined as the total number of
hypoglycemia during the study period (any glucose self-
measurement < 4.0 mmol/L or symptoms which the pa-
tients recognises as hypoglycemia and clinically judged by
the investigator as hypoglycemia)) 4) severe hypoglycemia
(defined by help needed from others, seizure, or coma) 5)
alpha and beta cell function (between group comparison
of glucose, insulin, C-peptide and glucagon levels, mea-
sured after standardised meal) 6) cardiovascular analysis;
change in blood pressure (mean ambulant 24 hour arterial
pressure) and change in plasma lipids 7) change in skin
Advanced glycation end products (AGEs) (measured as
skin-autofluorescence by the AGE-reader) [22,23].
Adverse events (AE): any (worsening of an) undesir-
able sign, symptom, or medical condition that was noted
by the patient occurring after starting the study drug
even if the event was not considered to be related to the
study drug.
Serious adverse events (SAE): AE judged as medically
significant, requiring in-patient hospitalization, prolonga-
tion of existing hospitalization, or resulting in persistent
or significant disability or incapacity or are life-threatening
or fatal.
Study procedures
Age, BMI, duration of DM, medication use, history of dia-
betic complications, blood pressure, prior hypoglycemia
(defined as symptomatic hypoglycemia in the past year),
HbA1c, glucose variability and laboratory values were re-
corded at baseline. Patients were seen every 4 weeks in the
out-patient clinic in our academic hospital and with tele-
phone consultation every week. Drug accountability and
laboratory measurements were performed at 8 and
16 weeks. CGM and ambulant blood pressure measure-
ment were repeated at the end of the study. At the end
of the study a standardised mixed meal test (MMT) wasperformed. Patients arrived fasting at the outpatient clinic
and took their medication (metformin and study medica-
tion) at t = 0, after blood samples were drawn as a baseline
(t = 0). At t = 30 blood samples were drawn again and they
consumed a standardized breakfast within 15 minutes (con-
taining 522 Kcal; 27 gr protein, 60 gr carbohydrates, 18 gr
fat). Blood samples for glucose, insulin, C-peptide and glu-
cagon were then drawn at t = 45, 60, 90, 120, 150 and
210 minutes. Insulin and C-peptide were measured using
an electrochemiluminescence immunoassay on the Modu-
lar E170 (Roche Diagnostics GmbH, D-68298 Mannheim,
Germany). Finally glucagon was measured with a com-
petitive radioimmunoassay (Glucagon KGND1, Siemens
Healthcare Diagnostics Inc, Los Angeles, USA).
The study was conducted using Good Clinical Practice
according to the declaration of Helsinki. The protocol was
approved by the ethics committee of the UMCUtrecht
and all patients provided written informed consent. This
investigator-driven study was designed, performed and
analysed by the researchers of the UMCUtrecht. Novartis
provided study medication and a research grant. The
protocol of this trial was published before start of the trial
at www.trialregister.nl (NTR2022).
Sample size calculation
The group size was based on the primary study parameter:
the absolute difference in daily insulin dose of long-acting
insulin between the two groups at the end of the trial. A
previous study in patients starting on once-daily insulin
showed a mean insulin glargine dose of 57 +/− 15 units
[24]. A meaningful decrease would be a difference of at
least 14 units. A similar decrease (25%) in insulin dose has
been observed when adding metformin to existing insulin
treatment [25]. With a beta of 0.2 and a one-sided alpha
of 0.05, the minimum number of patients in each group is
15. To correct for unforeseen circumstances, we planned
to include 20 patients in each group.
Statistics
Results are presented as median and range, categorical pa-
rameters as percentages. Areas under the curve of glucose,
insulin, C-peptide and glucagon were calculated using the
trapezoidal method. Since we did not meet our intended
sample size results are presented in a pure descriptive way.
Additional files
Additional file 1: Figure S1. Randomization scheme of the trial.
Additional file 2: Figure S2. Glucose, insulin, C-peptide and glucagon
levels after mixed meal test.
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